지역사회 노인에서 아밀로이드 PET 양성 예측에 대한 주관적 기억력 저하 설문의 유용성
Usefulness of a Memory Complaint Questionnaire for Predicting Amyloid PET Positivity in Community-Dwelling Older Adults
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study aimed to assess the usefulness of a memory complaint questionnaire for predicting amyloid PET positivity in community-dwelling older adults. Methods: We recruited community-dwelling older adults without history of dementia who wished to participate in the study based on voluntary consent. We performed the Seoul Neuropsychological Screening Battery-Core (SNSB-C), Memory Age-associated Complaint Questionnaire (MACQ), Apolipoprotein E (ApoE) genotyping, and amyloid PET. According to the result of the SNSB-C, participants with objective cognitive impairment were excluded, and finally 124 participants were included in this study. We used receiver operating characteristic (ROC) curve and calculated area under the ROC curve (AUC) to evaluate usefulness of the MACQ compared to the result of ApoE genotyping for predicting amyloid PET positivity in cognitively unimpaired community-dwelling older adults. Results: The mean age of the study participants was 73.3 years, and 69.4% were female. ROC curve with MACQ score and with ApoE4 carrier was created and AUC of each model was calculated. AUC value was 0.660 for MACQ score, and 0.695 for ApoE4 carrier. There was no statistically significant difference in AUC value (p=0.494). Conclusion: In community-dwelling older adults without objective cognitive decline, the memory complaint questionnaire― MACQ showed no significant difference with ApoE4 carrier for predicting amyloid PET positivity.
Abstract
Objective: This study aimed to assess the usefulness of a memory complaint questionnaire for predicting amyloid PET positivity in community-dwelling older adults. Methods: We recruited community-dwelling older adults without history of dementia who wished to participate in the study based on voluntary consent. We performed the Seoul Neuropsychological Screening Battery-Core (SNSB-C), Memory Age-associated Complaint Questionnaire (MACQ), Apolipoprotein E (ApoE) genotyping, and amyloid PET. According to the result of the SNSB-C, participants with objective cognitive impairment were excluded, and finally 124 participants were included in this study. We used receiver operating characteristic (ROC) curve and calculated area under the ROC curve (AUC) to evaluate usefulness of the MACQ compared to the result of ApoE genotyping for predicting amyloid PET positivity in cognitively unimpaired community-dwelling older adults. Results: The mean age of the study participants was 73.3 years, and 69.4% were female. ROC curve with MACQ score and with ApoE4 carrier was created and AUC of each model was calculated. AUC value was 0.660 for MACQ score, and 0.695 for ApoE4 carrier. There was no statistically significant difference in AUC value (p=0.494). Conclusion: In community-dwelling older adults without objective cognitive decline, the memory complaint questionnaire― MACQ showed no significant difference with ApoE4 carrier for predicting amyloid PET positivity.
참고문헌 (41)
- Jonker C, "Memory complaints and memory impairment in older individuals", J Am Geriatr Soc, 44, pp.44~49 (1996)
- Larrabee GJ, "Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function", Int Psychogeriatr, 6, pp.95~104 (1994)
- Jessen F, "A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease", Alzheimers Dement, 10, pp.844~852 (2014)
- Mitchell AJ, "Risk of dementia and mild cognitive impairment in older people with subjective memory complaints : meta-analysis", Acta Psychiatr Scand, 130, pp.439~451 (2014)
- Eckerström M, "Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer’s disease in a memory clinic sample", Alzheimers Dement(Amst), 8, pp.96~107 (2017)
- Snitz BE, "Risk of progression from subjective cognitive decline to mild cognitive impairment : the role of study setting", Alzheimers Dement, 14, pp.734~742 (2018)
- Wolfsgruber S, "Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline : cross-sectional comparison of three European memory clinic samples", Alzheimers Res Ther, 11, pp.8~ (2019)
- Dubois B, "Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria", Alzheimers Dement, 12, pp.292~323 (2016)
- Jack CR Jr, "NIA-AA research framework : toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
- Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer’s disease", N Engl J Med, 367, pp.795~804 (2012)
- Clark CM, "Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-βplaques : a prospective cohort study", Lancet Neurol, 11, pp.669~678 (2012)
- Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
- Furukawa K, "Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227 : comparison to FDG-PET", J Neurol, 257, pp.721~727 (2010)
- Pike KE, "Beta-amyloid imaging and memory in non-demented individuals : evidence for preclinical Alzheimer’s disease", Brain, 130(Pt 11), pp.2837~2844 (2007)
- Burnham SC, "A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease : results from the AIBL study", Mol Psychiatry, 19, pp.519~526 (2014)
- Ovod V, "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis", Alzheimers Dement, 13, pp.841~849 (2017)
- Jack CR Jr, "Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span", JAMA Neurol, 72, pp.511~519 (2015)
- Jansen WJ, "Prevalence of cerebral amyloid pathology in persons without dementia : a meta-analysis", JAMA, 313, pp.1924~1938 (2015)
- Ossenkoppele R, "Prevalence of amyloid PET positivity in dementia syndromes : a meta-analysis", JAMA, 313, pp.1939~1950 (2015)
- Gottesman RF, "The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE", Neurology, 87, pp.473~480 (2016)
- Choi YH, "Distributions of ACE and APOE polymorphisms and their relations with dementia status in Korean centenarians", J Gerontol A Biol Sci Med Sci, 58, pp.M227~31 (2003)
- Brunet HE, "Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography?", Alzheimers Dement(Amst), 11, pp.M424~ (2019)[DOI]
- Shokouhi S, "The relationship between domain-specific subjective cognitive decline and Alzheimer’s pathology in normal elderly adults", Neurobiol Aging, 81, pp.22~29 (2019)
- Jessen F, "The characterisation of subjective cognitive decline", Lancet Neurol, 19, pp.271~278 (2020)
- Rabin LA, "Subjective cognitive decline in older adults : an overview of self-report measures used across 19 international research studies", J Alzheimers Dis, 48(S1), pp.S63~86 (2015)
- Crook TH, "Assessment of memory complaint in age-associated memory impairment : the MAC-Q", Int Psychogeriatr, 4, pp.165~176 (1992)
- Morris JC, "APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging", Ann Neurol, 67, pp.122~131 (2010)
- Thomas KR, "MCI-to-normal reversion using neuropsychological criteria in the Alzheimer’s Disease Neuroimaging Initiative", Alzheimers Dement, 15, pp.1322~1332 (2019)
- Jak AJ, "Quantification of five neuropsychological approaches to defining mild cognitive impairment", Am J Geriatr Psychiatry, 17, pp.368~375 (2009)
- Bondi MW, "Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates", J Alzheimers Dis, 42, pp.275~289 (2014)
- Folstein MF, "“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician", J Psychiatr Res, 12, pp.189~198 (1975)
- Kang Y, "A validity study on the Korean minimental state examination(K-MMSE)in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Seoul neuropsychological screening battery-core (SNSB-C), "Kang Y", Human Brain Research & Consulting Co, ~ (2015)
- 장승민, "Constructing a Composite Score for the Seoul Neuropsychological Screening Battery-Core", Dementia and Neurocognitive Disorders(대한치매학회지), 14(4), pp.137~142 (2015), 대한치매학회[DOI]
- 송민지, "주관적 기억장애의 기억문제 호소 양상과 인지기능 및 정서 특성", Dementia and Neurocognitive Disorders(대한치매학회지), 10(4), pp.125~136 (2011), 대한치매학회
- Morris JC, "The clinical dementia rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Choi SH, "Estimating the validity of the Korean version of expanded clinical dementia rating(CDR)scale", J Korean Neurol Assoc, 19, pp.585~591 (2001)
- Nguyen Ho PT, "Predicting amyloid-beta pathology in the general population", Alzheimers Dement (2023)
- Lee JH, "Prediction of cerebral amyloid with common information obtained from memory clinic practice", Front Aging Neurosci, 10, pp.309~ (2018)
- Timmers T, "Amyloid PET and cognitive decline in cognitively normal individuals : the SCIENCe project", Neurobiol Aging, 79, pp.50~58 (2019)
- Petersen RC, "Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community", JAMA Neurol, 73, pp.85~92 (2016)